Immunocore Holdings plc (NASDAQ:IMCR) Shares Bought by Woodline Partners LP

Woodline Partners LP raised its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 19.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 328,059 shares of the company's stock after purchasing an additional 53,378 shares during the quarter. Woodline Partners LP owned about 0.66% of Immunocore worth $9,678,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in IMCR. Groupama Asset Managment acquired a new position in shares of Immunocore in the 4th quarter valued at $17,700,000. Deep Track Capital LP acquired a new position in shares of Immunocore in the 4th quarter valued at $15,322,000. Tang Capital Management LLC boosted its holdings in shares of Immunocore by 40.7% in the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Immunocore during the 4th quarter valued at $11,897,000. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after acquiring an additional 200,373 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

Immunocore Stock Up 0.4%

Shares of IMCR traded up $0.13 during midday trading on Wednesday, hitting $32.17. The company had a trading volume of 216,708 shares, compared to its average volume of 390,856. The company's 50 day moving average price is $29.09 and its 200 day moving average price is $29.97. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -34.05 and a beta of 0.75. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $49.05. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. During the same quarter in the prior year, the firm earned ($0.49) EPS. The company's revenue for the quarter was up 33.6% compared to the same quarter last year. On average, equities research analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on IMCR. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Oppenheimer lifted their target price on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Morgan Stanley restated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a report on Friday, March 7th. Needham & Company LLC restated a "buy" rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Insider Activity at Immunocore

In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 10.40% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.